NESH protein expression switches to the adverse effect of imatinib mesylate
Open accessAbstract
NESH protein expression switches to the adverse effect of imatinib mesylate
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Treatment of SRD cells overexpressing ABI3 with a tyrosine kinase inhibitor imatinib mesylate markedly promotes formation of invadopodia and enhances the metastatic potential.
“In contrast, treatment of SRD cells overexpressing ABI3 with a tyrosine kinase inhibitor imatinib mesylate markedly promotes formation of invadopodia, actin-rich ventral membrane protrusions with extracellular matrix-degrading activity, and enhances the metastatic potential (18,23).”
From Microglia express ABI3 in the brains of Alzheimer's disease and Nasu-Hakola disease (2017) · cites this paper as [23]
The study description and Figure 1 caption report that imatinib-treated NESH/SRD cells produced significantly more lung tumor nodules than controls, supporting enhanced metastatic potential. The passages retrieved do not report increased invadopodia formation or establish that the protrusions described in the citing sentence were observed in these cells (section labeled Abstract and Figure 1 caption; page numbers unavailable). (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 1
- Naoko Okumura Hitomi Yoshida Yuka Kajiya Yasuko Kitagishi Department of Environmental Health, Nara Women's University, KitaUoya-Nishimachi, Nara 630-8506, Japan Naoki Shirafuji Department of Hematology/Oncology, Teikyo University School of Medicine, Tokyo, Japan 1574-7891/$ -see front matter ª 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. doi:10.1016/j.molonc.2008.03.003
Cited by
Sorted by citations
The NESH/Abi-3-based WAVE2 complex is functionally distinct from the Abi-1-based WAVE2 complex
Sekino, S., Kashiwagi, Y., Kanazawa, H., Takada, K., Baba, T., Sato, S., Inoue, H., Kojima, M., & Tani, K. (2015) · Cell Communication and Signaling · doi:10.1186/s12964-015-0119-5 · Cited by 43 · see citing works
Microglia express ABI3 in the brains of Alzheimer's disease and Nasu-Hakola disease
Satoh, J.-I., Kino, Y., Yanaizu, M., Tosaki, Y., Sakai, K., Ishida, T., & Saito, Y. (2017) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2017.01073 · Cited by 55 · see citing works
- Authors
- Matsuda, S., Ichigotani, Y., Okumura, N., Yoshida, H., Kajiya, Y., Kitagishi, Y., & Shirafuji, N.
- Affiliations
- Nagoya University (JP)
- Inserm (FR)
- Nara Women's University (JP)
- Teikyo University Hospital (JP)
- Corresponding author
- Matsuda, Satoru
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2008-03-20
- Volume
- 2
- Issue
- 1
- Pages
- 16-19
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- PMC
- PMC5527794
- OpenAlex
- W2126173580
- Cited by
- 5
- References
- 0
- Citations by year
- 2024: 1 · 2017: 1 · 2015: 1 · 2012: 1
- FWCI
- 0.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Molecular Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Cancer Mechanisms and Therapy
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- nesh, imatinib mesylate, adverse drug reactions, protein expression, drug toxicity
- MeSH terms
- Imatinib Mesylate, Benzamides, Humans, Lung Neoplasms, Neoplasm Metastasis, Piperazines, Pyrimidines, Gene Expression, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
